Form 4: Vera Therapeutics CFO Sean Grant Reports Stock and Option Awards

Sean Grant, CFO of Vera Therapeutics, reports the acquisition of stock and option awards, including 26,900 shares of Class A Common Stock underlying restricted stock units and options to purchase 53,800 shares.

Summary

• On February 18, 2025, Sean Grant, the CFO of Vera Therapeutics, reported changes in his beneficial ownership of the company's securities.
• He acquired 26,900 shares of Class A Common Stock underlying restricted stock units (RSUs) under the company's 2021 Equity Incentive Plan.
• These RSUs vest in equal installments on February 20 of 2026, 2027, 2028, and 2029, contingent upon his continued service.
• Grant also acquired options to purchase 53,800 shares of Class A Common Stock at an exercise price of $29.18.
• These options vest monthly, starting March 18, 2025, over a four-year period, also subject to continuous service.
• Following these transactions, Grant directly owns 93,237 shares of Class A Common Stock and indirectly owns 5,000 shares through a trust.
• He also directly holds options for 53,800 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedules of the RSUs and options incentivize continued service and commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the equity awards.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key personnel. The vesting schedules are designed to align management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in biotech companies like Vera Therapeutics.
• Companies such as Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans to incentivize their leadership teams.
• The vesting schedules described are typical, with multi-year vesting periods to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates